Sonelokimab is under clinical development by MoonLake Immunotherapeutics and currently in Phase II for Psoriatic Arthritis. According to GlobalData, Phase II drugs for Psoriatic Arthritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sonelokimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sonelokimab overview

Sonelokimab (M-1095) is under development for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis(r-axSpA) and hidradenitis suppurativa. The drug candidate is administered subcutaneously. M1095 is a trivalent bi-specific nanobody that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F. The drug candidate is developed on basis of nanobody technology. It was also under development for rheumatoid arthritis.

MoonLake Immunotherapeutics overview

MoonLake Immunotherapeutics (MoonLake), formerly Helix Acquisition, is a biopharmaceutical company that develops and markets medicines for immunologic diseases for the treatment of inflammatory skin and joint diseases. The company is headquartered in Zug, Switzerland.

For a complete picture of Sonelokimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.